Allarity Therapeutics Inc (ALLR)

May 18, 2026

Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance

May 18, 2026

May 15, 2026

Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2026

May 15, 2026

Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative

May 15, 2026

May 15, 2026

Allarity Therapeutics Q1 net loss per share narrows - TradingView

May 15, 2026

May 15, 2026

U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan

May 15, 2026

May 15, 2026

Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

May 15, 2026

Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan

May 15, 2026

May 14, 2026

Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan

May 14, 2026

May 14, 2026

Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com

May 14, 2026

May 11, 2026

Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan

May 11, 2026

May 11, 2026

Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan

May 11, 2026

May 08, 2026

Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart

May 08, 2026

May 08, 2026

Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks

May 08, 2026

May 08, 2026

Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan

May 08, 2026

May 08, 2026

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times

May 08, 2026

May 08, 2026

Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative

May 08, 2026

May 08, 2026

Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan

May 08, 2026

May 07, 2026

Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan

May 07, 2026

May 07, 2026

PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

May 07, 2026

May 06, 2026

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile

May 06, 2026

May 06, 2026

Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart

May 06, 2026

May 06, 2026

Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan

May 06, 2026

May 05, 2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network

May 05, 2026

May 05, 2026

Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa

May 05, 2026

May 05, 2026

Allarity advances stenoparib manufacturing for pivotal trial - Investing.com India

May 05, 2026

May 05, 2026

Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan

May 05, 2026

May 05, 2026

What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05Earnings Breakout Stocks - Newser

May 05, 2026

Apr 30, 2026

[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Apr 30, 2026

Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan

Apr 30, 2026

Apr 30, 2026

Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan

Apr 30, 2026

Apr 30, 2026

Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan

Apr 30, 2026

Apr 28, 2026

USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan

Apr 28, 2026

Apr 27, 2026

Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK

Apr 27, 2026

Apr 27, 2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network

Apr 27, 2026

Apr 27, 2026

Allarity receives USPTO patent notice for stenoparib diagnostic By Investing.com - Investing.com Australia

Apr 27, 2026

Apr 27, 2026

Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office - marketscreener.com

Apr 27, 2026

Apr 27, 2026

SEC Form 424B3 filed by Allarity Therapeutics Inc. - Quantisnow

Apr 27, 2026

Apr 27, 2026

255,103 Shares Registered for Resale by 3i, LP — Allarity (NASDAQ: ALLR) - Stock Titan

Apr 27, 2026

Apr 27, 2026

[EFFECT] Allarity Therapeutics, Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 24, 2026

Allarity Therapeutics (NASDAQ: ALLR) updates auditor consent in S-3/A - Stock Titan

Apr 24, 2026

Apr 23, 2026

ALLR (Allarity Therapeutics Inc.) reports narrower Q3 2025 loss than expected, but shares dip slightly in today’s trading.Earnings Miss - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Allarity Therapeutics (NASDAQ: ALLR) highlights new stenoparib and DRP® data from AACR 2026 - Stock Titan

Apr 22, 2026

Apr 22, 2026

Allarity presents cancer drug data at AACR meeting By Investing.com - Investing.com India

Apr 22, 2026

Apr 21, 2026

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer - Investing News Network

Apr 21, 2026